Skip to main content

Research Repository

Advanced Search

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy

O’Neill, Daniel; Jones, Dominic; Wade, Mark; Grey, James; Nakjang, Sirintra; Guo, Wenrui; Cork, David; Davies, Barry R.; Wedge, Steve R.; Robson, Craig N.; Gaughan, Luke

Authors

Daniel O’Neill

Dominic Jones

Profile Image

Dr Mark Wade M.Wade@hull.ac.uk
Senior Lecturer in Molecular Genetics

James Grey

Sirintra Nakjang

Wenrui Guo

David Cork

Barry R. Davies

Steve R. Wedge

Craig N. Robson

Luke Gaughan



Abstract

The persistence of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the unmet clinical need for the development of more effective AR targeting therapies. A key mechanism of therapy-resistance is by selection of AR mutations that convert anti-androgens to agonists enabling the retention of androgenic signalling in CRPC. To improve our understanding of these receptors in advanced disease we developed a physiologically-relevant model to analyse the global functionality of AR mutants in CRPC. Using the bicalutamide-activated ARW741L/C mutation as proof of concept, we demonstrate that this mutant confers an androgenic-like signalling programme and growth promoting phenotype in the presence of bicalutamide. Transcriptomic profiling of ARW741L highlighted key genes markedly up-regulated by the mutant receptor, including TIPARP, RASD1 and SGK1. Importantly, SGK1 expression was found to be highly expressed in the KUCaP xenograft model and a CRPC patient biopsy sample both of which express the bicalutamide-activated receptor mutant. Using an SGK1 inhibitor, ARW741L transcriptional and growth promoting activity was reduced indicating that exploiting functional distinctions between receptor isoforms in our model may provide new and effective therapies for CRPC patients.

Citation

O’Neill, D., Jones, D., Wade, M., Grey, J., Nakjang, S., Guo, W., …Gaughan, L. (2015). Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. Oncotarget, 6(28), 26029-26040. https://doi.org/10.18632/oncotarget.4347

Journal Article Type Article
Acceptance Date Jul 8, 2015
Online Publication Date Jul 18, 2015
Publication Date Sep 22, 2015
Deposit Date Feb 4, 2019
Publicly Available Date Feb 5, 2019
Journal Oncotarget
Print ISSN 1949-2553
Electronic ISSN 1949-2553
Publisher Impact Journals
Peer Reviewed Peer Reviewed
Volume 6
Issue 28
Pages 26029-26040
DOI https://doi.org/10.18632/oncotarget.4347
Keywords Prostate cancer; Androgen receptor; Mutation; Anti-androgen-resistance; SGK1
Public URL https://hull-repository.worktribe.com/output/1271261
Publisher URL http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=4347&pubmed-linkout=1

Files





You might also like



Downloadable Citations